Production (Stage)
X4 Pharmaceuticals, Inc.
XFOR
$3.10
-$0.13-4.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.33% | 73.27% | 75.17% | 62.30% | 71.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.46% | 33.89% | 22.34% | 23.13% | 20.82% |
| Operating Income | 1.69% | -31.51% | -21.30% | -22.57% | -20.82% |
| Income Before Tax | 111.58% | 63.26% | 84.99% | 113.59% | -34.31% |
| Income Tax Expenses | 249.46% | 297.44% | 44.07% | 380.00% | 933.33% |
| Earnings from Continuing Operations | 111.32% | 62.98% | 84.92% | 113.52% | -34.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.32% | 62.98% | 84.92% | 113.52% | -34.39% |
| EBIT | 1.69% | -31.51% | -21.30% | -22.57% | -20.82% |
| EBITDA | 2.44% | -31.28% | -21.30% | -22.76% | -21.09% |
| EPS Basic | 110.85% | 69.37% | 89.36% | 108.26% | 46.99% |
| Normalized Basic EPS | 35.87% | -17.38% | 23.50% | 58.10% | 46.88% |
| EPS Diluted | 110.38% | 68.84% | 88.89% | 107.90% | 46.95% |
| Normalized Diluted EPS | 35.89% | -17.36% | 23.52% | 58.11% | 46.88% |
| Average Basic Shares Outstanding | 5.88% | 13.20% | 30.63% | 59.66% | 109.23% |
| Average Diluted Shares Outstanding | 6.04% | 13.25% | 30.69% | 59.73% | 109.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |